Replies to post #1749 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC 4Q20_rev=$11.1M—12/31/20_cash=$436.5M—flat_vs_9/30/20_due_to_3.3M-sh_($90M)_ATM_sale:

https://investors.revance.com/news-releases/news-release-details/revance-reports-fourth-quarter-and-full-year-2020-financial

No new news on the FDA manufacturing inspection for the Daxi BLA, which has been delayed by COVID travel restrictions.

4Q20 dermal-filler sales of $10.0M was inline with RVNC’s announcement on 1/7/21 (#msg-160748323).

Cash operating expenses of $69M for 4Q20 and $226M for full-year 2020 were inline with the company’s prior guidance.

For full-year 2021, RVNC is today issuing guidance for cash operating expenses (excluding product sales and other revenue) of $270-285M.